Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
beta cell function
phase I-II study
randomized trial
type 1 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
12
05
2022
received:
08
04
2022
accepted:
17
05
2022
pubmed:
20
5
2022
medline:
4
8
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
To evaluate the ability of ladarixin (LDX, 400 mg twice-daily for three cycles of 14 days on/14 days off), an inhibitor of the CXCR1/2 chemokine receptors, to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes. A double-blind, randomized (2:1), placebo-controlled study was conducted in 45 males and 31 females (aged 18-46 years) within 100 days of the first insulin administration. The primary endpoint was the area under the curve (AUC) for C-peptide in response to a 2-hour mixed meal tolerance test (AUC In total, 26/26 (100%, placebo) and 49/50 (98%, LDX) patients completed week 13. The mean change from baseline to week 13 in C-peptide AUC In newly diagnosed patients with type 1 diabetes, short-term LDX treatment had no appreciable effect on preserving residual beta cell function.
Identifiants
pubmed: 35589610
doi: 10.1111/dom.14770
pmc: PMC9540558
doi:
Substances chimiques
2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide
0
C-Peptide
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Receptors, Interleukin-8
0
Sulfonamides
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1840-1849Informations de copyright
© 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2019 Aug 15;381(7):603-613
pubmed: 31180194
Diabetologia. 2021 Jun;64(6):1189-1200
pubmed: 33661335
Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224
pubmed: 33662334
Diabetes. 2019 Jun;68(6):1267-1276
pubmed: 30967424
PLoS One. 2011;6(11):e26471
pubmed: 22102862
N Engl J Med. 2020 Nov 19;383(21):2007-2017
pubmed: 33207093
N Engl J Med. 2005 Jun 23;352(25):2598-608
pubmed: 15972866
Pediatr Diabetes. 2011 Nov;12(7):656-67
pubmed: 21518168
Diabetes. 2013 Jun;62(6):2072-7
pubmed: 23349491
Br J Pharmacol. 2012 Jan;165(2):436-54
pubmed: 21718305
Immunol Lett. 2012 Jul 30;145(1-2):68-78
pubmed: 22698186
J Immunol. 2016 Oct 15;197(8):3293-3301
pubmed: 27619992
Diabetes. 2015 Apr;64(4):1329-40
pubmed: 25315007
Lancet Child Adolesc Health. 2019 Jan;3(1):35-43
pubmed: 30409691
Lancet. 2013 Jun 1;381(9881):1905-15
pubmed: 23562090
Front Endocrinol (Lausanne). 2021 Feb 08;11:606332
pubmed: 33628197
JCI Insight. 2021 Nov 8;6(21):
pubmed: 34747368
J Diabetes Investig. 2016 Sep;7(5):652-63
pubmed: 27181374
Diabetes Care. 2009 Dec;32(12):e153; author reply e154
pubmed: 19940216
Diabetes Obes Metab. 2022 Sep;24(9):1840-1849
pubmed: 35589610
Sci Transl Med. 2016 Sep 14;8(356):356ra119
pubmed: 27629486
Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94
pubmed: 24622414
Diabetes Care. 2009 Jul;32(7):1244-9
pubmed: 19366957
Diabetologia. 2013 Feb;56(2):391-400
pubmed: 23086558
N Engl J Med. 2009 Nov 26;361(22):2143-52
pubmed: 19940299
Nat Med. 2013 Jan;19(1):65-73
pubmed: 23242473
JCI Insight. 2018 Sep 20;3(18):
pubmed: 30232284
Lancet. 2011 Jul 30;378(9789):412-9
pubmed: 21719096